Overactive bladder is very prevalent in postmenopausal women. The current study is designed to investigate whether a new drug may offer safe and effective treatment.
Clinical development of MK-0634 was discontinued. Study MK-0634-027 was a safety follow-up study to determine if there were any ocular effects of MK-0634 in participants from the United Kingdom who were exposed to MK-0634 during the 007 study.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
848
one capsule orally, once daily in morning
one or three capsules orally, once daily in morning
one, two, three or four capsules orally once daily in morning
Change from baseline in the number of micturitions per day averaged over a diary card week (4 to 10 days)
Time frame: Baseline and Week 8
Proportion of participants with abnormal retinal photography (Follow-up Study 007 only)
Time frame: Day 1 of Follow-up
Proportion of participants with abnormal visual field test (Follow-up Study 007 only)
Time frame: Day 1 of Follow-up
Change from baseline in the number of total incontinence episodes
Time frame: Baseline and Week 8
Number of urge-incontinence episodes
Time frame: Up to 8 weeks
Number of urgency episodes per day averaged over a diary card week (4 to 10 days)
Time frame: up to 8 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.